KITE-197 / Gilead - LARVOL DELTA

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov) - P=N/A | N=1000 | Enrolling by invitation | Sponsor: Kite, A Gilead Company | N=700 ➔ 1000

Enrollment change • Hematological Disorders • Hematological Malignancies • Oncology

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Kite, A Gilead Company | Active, not recruiting ➔ Recruiting

Enrollment open • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - P1 | N=39 | Active, not recruiting | Sponsor: Kite, A Gilead Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Kite, A Gilead Company | Trial primary completion date: Mar 2025 ➔ Dec 2027

Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Kite, A Gilead Company

Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Kite, A Gilead Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - P1 | N=39 | Not yet recruiting | Sponsor: Kite, A Gilead Company

New P1 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology